We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ip Group Plc | LSE:IPO | London | Ordinary Share | GB00B128J450 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.60 | 1.15% | 52.70 | 52.70 | 53.10 | 53.40 | 51.80 | 52.40 | 1,728,185 | 16:29:52 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | -140.1M | -174.4M | -0.1751 | -3.01 | 518.86M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/8/2024 08:40 | Maybe a mixed bag and trying to understand the result. | bjfanc | |
13/8/2024 08:35 | It should have read out by now. IP will know what's going on. | bagpuss67 | |
13/8/2024 08:13 | Edison set the expectation that Istesso’s Phase 2b trial for its lead drug Leramistat (MBS2320) in rheumatoid arthritis would read out in H1 2024. The study completed in Jan 2024. The Phase 2 trial in idiopathic pulmonary fibrosis (IPF) is also underway and expected to complete in September 2024. Unfortunately just a waiting game until Istesso is in a position to annouce results | tvh123 | |
13/8/2024 07:05 | Have to ask why the selling and is it related to some entity having a problem and needing to cash out now? So many things moving all at once. | p1nkfish | |
13/8/2024 06:44 | Assuming I am reading the rns correctly, it's interesting to see that yesterday, before buyback started at approx 9:08, approx 400k had already been bought. Also out of a total of approx 6m traded IPGroup bought 940k, suggesting that there are others buying down here. | bamboo2 | |
12/8/2024 09:44 | Fair comment - but these markets are very unforgiving | bagpuss67 | |
12/8/2024 08:50 | Although you could argue a bad result is already in the price. | hugepants | |
12/8/2024 08:45 | Yep. That's my worry... See earlier posts. | bagpuss67 | |
12/8/2024 08:43 | The Istesso arthritis result is going to be key since this is the biggest holding at 11p per share. | hugepants | |
12/8/2024 08:15 | Looking positive this am | bagpuss67 | |
10/8/2024 07:12 | Useful to determine if any action you take is a speculation or an investment to avoid deluding yourself before you even start. | p1nkfish | |
10/8/2024 07:11 | There's no way to 2nd guess. Speculation is the name of the game. | p1nkfish | |
10/8/2024 06:45 | I understand that in fact it's unusual for such a delay. Separately the mechanism of this drug has been tried before (to be fair only a quick read from someone), and not gone anywhere. Obviously I hope that there is nothing wrong and the trial read out is all OK and the drug gets further backing. In which case I also hope for a decent rerate. | bagpuss67 | |
09/8/2024 19:47 | Discount to enav is eye watering. If the arthritis read out is positive this will sky rocket | edwardt | |
09/8/2024 19:20 | undervalued just like peer group - will break out | japatrick | |
09/8/2024 15:49 | I have also topped up, first thing this morning, despite being overweight, and overweight ONT. | apple53 | |
09/8/2024 15:34 | All I remember reading was that results were due during 2024. Did anything state Summer? | p1nkfish | |
09/8/2024 15:05 | Bit concerned about the Istesso delay and indeed the quality/novelty of the drug in question. | bagpuss67 | |
09/8/2024 08:36 | IPO has the unloved syndrome for small uk shares. As they deal in small uk shares and all these are unloved hence the low price. It doesnt mean the assets they hold are bad its just the market. I hold IPO/Frontier/Duke/Me Which ever way you look at IPO its worth much more than the current share price. | ivyhedge | |
09/8/2024 08:15 | Over 9 million traded in just over the hour. | gemlotte55 | |
09/8/2024 08:00 | Looks like it could be. | bagpuss67 | |
09/8/2024 07:59 | back over 40p in short order | orinocor | |
09/8/2024 07:58 | that was the low point | orinocor | |
09/8/2024 07:57 | NAV is less if a problem to imho. I also think management are professionals. My beef is misalignment of incentives and a lack of what I would call fighting spirit to aggressively market IPO. | p1nkfish |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions